The Optical Remote Monitoring Blood Pressure Revolution ...at your Fingertip.
We're on a mission to make democratized blood pressure management via instant, ubiquitous, and accurate remote monitoring a reality
Try out OptiBP with our investigational use study!
Join our OptiBP Study and easily monitor your blood pressure using your phone! Download the Android OptiBP Study app now from Google Play to find out more.
The study is exclusively for the US and requires an Android phone and blood pressure cuff.
Biospectal Wins Coveted Health Innovator Selection @ SXSW 2022
SXSW 2022 has selected Biospectal to join its list of Innovation Award finalists from a huge number of entries for the award ceremony in Austin, TX on 14 March. Come talk with us about our fingertip optical sensing with OptiBP and Biodisc on Saturday at the Innovator’s showcase!
Biospectal to Debut Biodisc™ and Launch OptiBP for iOS Public Beta at CES 2022
All-in-one blood pressure monitoring device, Biodisc democratizes access and expands the reach of Biospectal’s blood pressure monitoring platform from smartphones and other connected mobile devices, to clinics, hospitals, work and home The Biospectal team is excited to announce the debut of Biodisc™, a stand-alone, sleekly-designed, all-in-one, blood pressure monitoring device at CES 2022. Biospectal also plans to announce the public beta launch of Biospectal OptiBP™ for iOS at CES 2022,
Biospectal OptiBP Named Winner in Fast Company’s First-Ever List of the Next Big Things in Tech
LAUSANNE, SWITZERLAND – NOVEMBER 18, 2021 – Biospectal SA, the remote patient monitoring biosensing software company, today announced the Biospectal OptiBP™ smartphone blood pressure monitoring app and data platform has been named a winner in the Health category for Fast Company’s Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape the future of their industries — from healthcare to agriculture to artificial intelligence and more.
Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink
Today we are happy to announce the closing of a CHF 4.0M($4.3M) round of seed funding led by digital health investor, SeedLink, with additional funding from LabCorp, Athensmed, Swiss based Privilege Ventures and other European and US investors. Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology worldwide. The funding we’ve received will accelerate Biospectal’s growth trajectory along with the
Biospectal Announces Two Independent Global Health Research and Validation Studies
We’re proud to announce two independent global research and validation studies which integrate the Biospectal OptiBP™ blood pressure measurement app. Currently underway in four low-resource countries, the studies center on the routine measurement and monitoring of blood pressure, assessment of hypertension during pregnancy, and enable global field testing and validation of Biospectal’s OptiBP smartphone app and data platform integration with the WHO’s Digital Antenatal Care module, following WHO SMART guidelines
Biospectal Wins a Coveted Spot on the Swiss National Mobile Startup Team at MWC Barcelona 2021
We’re excited to announce Biospectal has been chosen as one of 10 companies selected to represent Switzerland on the global stage at MWC Barcelona (June 28–July 1, 2021). We look forward to attending and meeting with top-notch investors and industry leaders at several of MWC’s key events, such as the 4YFN startup conference. Selected from nearly 100 applications, the companies chosen for Venture Leaders Mobile 2021 represent and highlight Switzerland’s
Supporters
